Vista Current Coverage

All Atossa Genetics, Inc. Articles

MARKET ALERT: Atossa Genetics Announces FDA Approval of Oral Endoxifen for “Expanded Access” as Post-Mastectomy Treatment for a U.S. Breast Cancer Patient

Sometimes called “compassionate use,” expanded access is a potential pathway for a patient with serious disease or condition, or an immediately life-threatening condition, to gain access to an investigational medical product (drug, biologic, or medical device) for treatment outside of clinical trials when no comparable...

FDA Approves First Immunotherapy for Breast Cancer

Last Friday the FDA approved Roche’s Tecentriq, an immunotherapy for cancer, to be used to treat breast cancer patients. This makes it the first immunotherapy to be approved for the treatment of this type of cancer. The approval does come with restrictions; it was only...

Vista Partners Publishes “Vista’s View” Weekly Market Update 3-9-19

Vista Partners has published “Vista’s View” Vista Partners’ Weekly Market Update 3-9-19!” Each weekly newsletter is written by Vista Partners’ Managing Director, John Heerdink.   Vista’s View includes an exclusive view on the stock market for the week, a “Stocks To Watch” section, featured stories that...